Shots:
- InnoCare has dosed the first patient with orelabrutinib in the P-III trial for the treatment of systemic lupus erythematosus (SLE), assessing its efficacy & safety against PBO, with the SRI-4 response rate at Wk. 52 as the 1EP
- Orelabrutinib was assessed in the P-IIb trial, which met its 1EP, where orelabrutinib (75mg, QD) showed improved SLE SRI-4 response at Wk. 48 (57.1% vs. 34.4%)
- Also, in a high-activity subgroup (BILAG ≥1A or ≥2B; SLEDAI-2K ≥4), the 75mg (QD) group achieved 68% SRI-4 response, a 43% absolute improvement vs PBO, with 71.1% reducing steroids to ≤7.5mg vs 43.6%
Ref: Globenewswire | Image: Innocare |Press Release
Related News: InnoCare Pharma Reports First Patient Dosing in P-II/III Trial of Soficitinib for Chronic Spontaneous Urticaria
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
